{
    "data": [
        {
            "id": "69a1bc2424c37e0001bc0c7a",
            "title": "Here&#39;s How Much You Would Have Made Owning General Dynamics Stock In The Last 5 Years",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\">General Dynamics (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/GD\" target=\"_blank\">GD</a>) has outperformed the market over the past 5 years by 3.78% on an annualized basis producing an average annual return of 15.88%. Currently, General Dynamics has a market capitalization of $95.71 billion. </p><!--/$--><!--$--><p class=\"block core-block\"><strong>Buying $100 In GD:</strong> If an investor had bought $100 of GD stock 5 years ago, it would be worth <strong>$209.74</strong> today based on a price of $353.98 for GD at the time of writing.</p><!--/$--><!--$--><h3 class=\"block core-block\">General Dynamics's Performance Over Last 5 Years</h3><!--/$--><!--$?--><template id=\"B:1\"></template><div></div><!--/$--><!--$--><p class=\"block core-block\">Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p><!--/$--><!--$--><p class=\"block core-block\"><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--></div></div>",
            "image": "",
            "link": "https://www.benzinga.com/insights/news/26/02/50932060/heres-how-much-you-would-have-made-owning-general-dynamics-stock-in-the-last-5-years",
            "pub_date": "2026-02-27 23:45:44",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a1bc2724c37e0001bc0c7e",
            "title": "OneMedNet Stock Skyrockets As It Rolls Out Next RWD Phase With Palantir Foundry",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\"><strong>OneMedNet</strong> <a class=\"ticker-link\" data-exchange=\"NASDAQ\" data-ticker=\"ONMD\" href=\"https://www.benzinga.com/quote/ONMD\" rel=\"noopener\" target=\"_blank\">(NASDAQ:</a><a class=\"ticker\" href=\"https://www.benzinga.com/quote/ONMD\" target=\"_blank\">ONMD</a>)<!-- --> shares are up on Friday following the company’s announcement of <a href=\"https://www.benzinga.com/pressreleases/26/02/g50926140/onemednet-announces-next-phase-of-commercial-launch-with-its-real-world-data-rwd-platform-powered-\" target=\"_blank\">the next phase</a> of its commercial launch for its Real-World Data (RWD) platform, which is powered by <strong>Palantir Technologies Inc.’s </strong><a class=\"ticker-link\" data-exchange=\"NASDAQ\" data-ticker=\"PLTR\" href=\"https://www.benzinga.com/quote/PLTR\" rel=\"noopener\" target=\"_blank\">(NASDAQ:</a><a class=\"ticker\" href=\"https://www.benzinga.com/quote/PLTR\" target=\"_blank\">PLTR</a>)<!-- --> Foundry.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>      • OneMedNet stock is charging ahead with explosive momentum. <a href=\"https://www.benzinga.com/quote/ONMD\" rel=\"noreferrer noopener\" target=\"_blank\">Why are ONMD shares rallying?</a></strong></p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">This development is contributing to a positive sentiment around the stock, even as broader markets are experiencing declines, with the S&amp;P 500 down 0.96%.</p><!--/$--><!--$--><p class=\"block core-block\">“Customer feedback has reinforced the platform’s performance, speed, and depth of discovery,” said CEO <strong>Aaron Green</strong>. “We believe this traction validates our strategy of combining conversational AI-driven search with scalable, prospective data feeds, strengthening customer confidence as we expand subscriptions and deliver fast, intuitive value for Real-World evidence generation.”</p><!--/$--><!--$--><h2 class=\"wp-block-heading\"><strong>Trials To Subscriptions</strong></h2><!--/$--><!--$--><p class=\"block core-block\">The company is actively converting customer evaluations into commercial subscriptions, which are expected to drive predictable growth and millions in “incremental” annual recurring revenue (ARR). </p><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--><!--$--><p class=\"block core-block\">With over 2,130 healthcare sites integrated into its iRWD platform, OneMedNet is set to enhance its subscription value through greater scale and real-time access to comprehensive regulatory-grade multimodal data.</p><!--/$--><!--$--><p class=\"block core-block\">The launch is expected to accelerate the adoption of its platform across life sciences and AI health innovators, providing customers with near real-time access to integrated clinical and longitudinal datasets. This strategic move aims to streamline workflows and enhance the speed of evidence generation, reinforcing OneMedNet’s position in the healthcare data landscape.</p><!--/$--><!--$--><p class=\"block core-block\">The broader market is experiencing a mixed day, with major indices like the Dow Jones down 1.41% and the Nasdaq down 0.90%. Despite this, the health care sector is showing some resilience, with a modest gain of 0.26%, indicating that OneMedNet’s positive news may be resonating well within this sector.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\"><strong>Technical Analysis</strong></h2><!--/$--><!--$--><p class=\"block core-block\">The stock is currently trading 12.5% below its 20-day simple moving average (SMA) and 20% below its 100-day SMA, indicating some short-term weakness. Over the past 12 months, shares have decreased significantly, reflecting broader market challenges, and are currently positioned closer to their 52-week lows than highs.</p><!--/$--><!--$--><p class=\"block core-block\">The RSI is at 50.00, which is considered neutral territory, suggesting the stock is neither overbought nor oversold at this time. Meanwhile, MACD is at 0.10, below its signal line at 0.15, indicating bearish pressure on the stock.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">The combination of neutral RSI and bearish MACD suggests mixed momentum, indicating that traders should watch for potential shifts in market sentiment.</p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong>Key Resistance</strong>: $1.50</li>\n<li><strong>Key Support</strong>: 75 cents</li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><strong>Analyst Consensus &amp; Recent Actions:</strong> The stock carries a N/A Rating. No recent analyst actions available.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>ONMD Price Action:</strong> OneMedNet shares were up 81.46% at $1.28 at the time of publication on Friday, according to <a href=\"https://pro.benzinga.com/dashboard\" target=\"_blank\">Benzinga Pro data</a>.</p><!--/$--><!--$--><!--/$--><!--$--><div class=\"bz-optimizely-campaign bz-optimizely-campaign-bottom-50932062\" data-nosnippet=\"true\"></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2026/02/27/Stock-Market-Graph-Trading-Analysis-Inve.jpeg",
            "link": "https://www.benzinga.com/markets/equities/26/02/50932062/onemednet-stock-skyrockets-as-it-rolls-out-next-rwd-phase-with-palantir-foundry",
            "pub_date": "2026-02-27 23:45:47",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a1b8ab24c37e0001bc08e7",
            "title": "If You Invested $100 In AstraZeneca Stock 5 Years Ago, You Would Have This Much Today",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\">AstraZeneca (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/AZN\" target=\"_blank\">AZN</a>) has outperformed the market over the past 5 years by 4.19% on an annualized basis producing an average annual return of 16.3%. Currently, AstraZeneca has a market capitalization of $321.64 billion. </p><!--/$--><!--$--><p class=\"block core-block\"><strong>Buying $100 In AZN:</strong> If an investor had bought $100 of AZN stock 5 years ago, it would be worth <strong>$211.72</strong> today based on a price of $207.47 for AZN at the time of writing.</p><!--/$--><!--$--><h3 class=\"block core-block\">AstraZeneca's Performance Over Last 5 Years</h3><!--/$--><!--$?--><template id=\"B:1\"></template><div></div><!--/$--><!--$--><p class=\"block core-block\">Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p><!--/$--><!--$--><p class=\"block core-block\"><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--></div></div>",
            "image": "",
            "link": "https://www.benzinga.com/insights/news/26/02/50931183/if-you-invested-100-in-astrazeneca-stock-5-years-ago-you-would-have-this-much-today",
            "pub_date": "2026-02-27 23:30:56",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a1b8d724c37e0001bc0930",
            "title": "Venture Global First Korean Deal Marks New LNG Era",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\"><strong>Venture Global</strong> <a class=\"ticker-link\" data-exchange=\"NYSE\" data-ticker=\"VG\" href=\"https://www.benzinga.com/quote/VG\" rel=\"noopener\" target=\"_blank\">(NYSE:</a><a class=\"ticker\" href=\"https://www.benzinga.com/quote/VG\" target=\"_blank\">VG</a>)<!-- --> shares are up on Friday morning following a significant announcement regarding <a href=\"https://www.benzinga.com/pressreleases/26/02/b50917157/venture-global-announces-new-long-term-lng-partnership-with-hanwha-of-korea\" target=\"_blank\">a new long-term partnership</a>. </p><!--/$--><!--$--><p class=\"block core-block\"><strong>      • Venture Global stock is showing downward pressure. <a href=\"https://www.benzinga.com/quote/VG\" rel=\"noreferrer noopener\" target=\"_blank\">What’s ahead for VG stock?</a></strong></p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">The company has entered into a 20-year sales and purchase agreement with <strong>Hanwha Aerospace</strong>, marking its first deal with a Korean entity.</p><!--/$--><!--$--><p class=\"block core-block\">This deal is expected to bolster its LNG supply capabilities in Asia as the market for liquefied natural gas continues to grow. </p><!--/$--><!--$--><p class=\"block core-block\">This new partnership aligns with Venture Global’s strategy to expand its footprint in the global energy market.</p><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\"><strong>Details</strong></h2><!--/$--><!--$--><p class=\"block core-block\">The agreement entails the purchase of 1.5 million tonnes per annum (MTPA) of U.S. liquefied natural gas starting in 2030, bringing Venture Global’s long-term contracted portfolio to over 46 MTPA. </p><!--/$--><!--$--><p class=\"block core-block\">CEO <strong>Mike Sabel</strong> expressed excitement about this partnership, emphasizing the importance of reliable, low-cost American LNG to meet growing global energy needs and strengthen the strategic energy partnership between the U.S. and South Korea.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">This collaboration comes as Venture Global continues to enhance its LNG production capabilities, with over 100 MTPA of capacity in various stages of production, construction, or development. </p><!--/$--><!--$--><p class=\"block core-block\">The company’s ongoing projects in Louisiana, including Calcasieu Pass and Plaquemines LNG, are integral to its strategy of supporting clean energy solutions globally.</p><!--/$--><!--$--><h2 class=\"wp-block-heading\"><strong>Technical Analysis</strong></h2><!--/$--><!--$--><p class=\"block core-block\">The broader market experienced a mixed performance on the previous trading day, with the <strong>Russell 2000</strong> down 0.63% and the <strong>S&amp;P 500 </strong>falling 0.13%. Despite this, Venture Global’s stock is moving higher, indicating that the positive news surrounding the LNG partnership may be driving investor interest independently of broader market trends.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">The stock is currently trading 9.8% below its 100-day simple moving average (SMA), suggesting some short-term weakness, while it is positioned closer to its 52-week highs than lows. Shares have increased 68% over the past 12 months, reflecting a strong long-term upward trend.</p><!--/$--><!--$--><p class=\"block core-block\">The RSI is at 44.45, which is considered neutral territory, indicating that the stock is neither overbought nor oversold. Meanwhile, MACD is at 0.15, below its signal line at 0.22, indicating bearish pressure on the stock.</p><!--/$--><!--$--><p class=\"block core-block\">The combination of neutral RSI and bearish MACD suggests mixed momentum.</p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong>Key Resistance</strong>: $10</li>\n<li><strong>Key Support</strong>: $9</li>\n</ul><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\"><strong>Earnings &amp; Analyst Outlook</strong></h2><!--/$--><!--$--><p class=\"block core-block\">The countdown is on: Venture Global is set to report earnings on March 2, 2026.</p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong>EPS Estimate</strong>: 34 cents (Up from 33 cents)</li>\n<li><strong>Revenue Estimate</strong>: $4.58 billion (Up from $1.52 billion)</li>\n<li><strong>Valuation</strong>: P/E of 10.8x (Indicates value opportunity)</li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><strong>Analyst Consensus &amp; Recent Actions:</strong> The stock carries a Buy Rating with an <a href=\"https://www.benzinga.com/quote/NYSE:VG/analyst-ratings\" target=\"_blank\">average price target</a> of $13.64. Recent analyst moves include:</p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong>Morgan Stanley</strong>: Initiated with Underweight (Target $8 on Feb. 24)</li>\n<li><strong>JP Morgan</strong>: Downgraded to Neutral (Raises target to $11 on Jan. 27)</li>\n<li><strong>UBS</strong>: Buy (Lowers target to $16 on Jan. 22)</li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><strong>VG Price Action:</strong> Venture Global shares were up 0.42% at $9.51 at publication on Friday, according to <a href=\"https://pro.benzinga.com/dashboard\" target=\"_blank\">Benzinga Pro data</a>.</p><!--/$--><!--$--><p class=\"block core-block\"><em>Photo: PeopleImages.com, Yuri A via Shutterstock</em></p><!--/$--><!--$--><div class=\"bz-optimizely-campaign bz-optimizely-campaign-bottom-50931248\" data-nosnippet=\"true\"></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2026/02/27/Complex-Deal-Structure.jpeg",
            "link": "https://www.benzinga.com/markets/large-cap/26/02/50931248/venture-global-first-korean-deal-marks-new-lng-era",
            "pub_date": "2026-02-27 23:31:39",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a1b77b24c37e0001bc07a0",
            "title": "Cathie Wood, Chase Coleman Bet On Block — Now Jack Dorsey Is Rewriting The Cost Curve",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\">Billionaire investors had already built exposure. The cost curve is now being rewritten. Shares of <strong>Block Inc</strong> <a class=\"ticker-link\" data-exchange=\"NYSE\" data-ticker=\"XYZ\" href=\"https://www.benzinga.com/quote/XYZ\" rel=\"noopener\" target=\"_blank\">(NYSE:</a><a class=\"ticker\" href=\"https://www.benzinga.com/quote/XYZ\" target=\"_blank\">XYZ</a>)<!-- --> surged roughly 20% premarket after CEO <strong>Jack Dorsey</strong> announced the company will cut nearly 4,000 employees — about 40% of its workforce — to become \"more compact, flat, and AI-focused.\"</p><!--/$--><!--$--><p class=\"block core-block\">The stock, currently up over 17% and trading at around $63.90 per share, entered the week down double digits year to date. Then Dorsey rewrote the operating model.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\">Billionaires Were Already Buying</h2><!--/$--><!--$--><p class=\"block core-block\">In the fourth quarter, <strong>ARK Investment Management</strong>, led by <strong>Cathie Wood</strong>, increased its Block stake by more than 26%, owning roughly 3.4 million shares.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Tiger Global Management</strong>, run by <strong>Chase Coleman</strong>, boosted its position nearly 44%, during the same period, holding about 6.4 million shares.</p><!--/$--><!--$--><p class=\"block core-block\">That positioning matters.</p><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--><!--$--><p class=\"block core-block\">Both managers have historically leaned into platform businesses with operating leverage inflection potential. Block's pivot may be exactly that.</p><!--/$--><!--$--><h2 class=\"wp-block-heading\">‘A Decision At This Scale Carries Risk’</h2><!--/$--><!--$--><p class=\"block core-block\">Dorsey didn't hide from the magnitude.</p><!--/$--><!--$--><p class=\"block core-block\">\"Today we're making one of the hardest decisions in the history of our company,\" he <a href=\"https://x.com/jack/status/2027129697092731343\" target=\"_blank\">wrote</a> on X, adding that the company is reducing from over 10,000 employees to just under 6,000. “A decision at this scale carries risk but so does standing still,” he noted.</p><!--/$--><!--$--><!--/$--><!--$--><p class=\"block core-block\">Dorsey emphasized the move isn't about financial stress. \"Our business is strong. Gross profit continues to grow.\"</p><!--/$--><!--$--><p class=\"block core-block\">Instead, he said AI tools are \"fundamentally changing what it means to build and run a company.\" He also rejected gradual cuts. \"Repeated rounds of cuts are destructive… I'd rather take a hard, clear action now.\"</p><!--/$--><!--$--><p class=\"block core-block\">That language signals something bigger than expense trimming.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">If AI enables smaller teams to generate the same — or greater — output, then margins structurally shift higher. That changes valuation frameworks.</p><!--/$--><!--$--><p class=\"block core-block\">Wood and Coleman were already betting on the platform. Now Dorsey is accelerating the earnings math.</p><!--/$--><!--$--><p class=\"block core-block\">And if this becomes a template across tech and fintech, XYZ may not just be cutting costs. It may be front-running a new corporate model.</p><!--/$--><!--$--><p class=\"block core-block\"><em>Image: Shutterstock</em></p><!--/$--><!--$--><div class=\"bz-optimizely-campaign bz-optimizely-campaign-bottom-50930882\" data-nosnippet=\"true\"></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2026/02/27/Block-Inc-.jpeg",
            "link": "https://www.benzinga.com/markets/hedge-funds/26/02/50930882/cathie-wood-chase-coleman-bet-on-block-now-jack-dorsey-is-rewriting-the-cost-curve",
            "pub_date": "2026-02-27 23:25:51",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        }
    ]
}